Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.
oncology
quality of life
randomized controlled trials
treatment toxicity
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
22
06
2020
revised:
13
07
2020
accepted:
22
07
2020
pubmed:
5
9
2020
medline:
20
7
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Anti-cancer drugs are approved typically on the basis of efficacy and safety as evaluated in phase III randomized trials (RCTs). Health-related quality of life (HRQoL) is a direct measure of patient benefit, but is under-reported. Here we explore associations with reporting of HRQoL data in phase III RCTs in common solid tumors. We searched ClinicalTrials.gov to identify phase III RCTs evaluating new drugs in adults with advanced cancers that completed accrual between January 2005 and October 2016. Data on HRQoL, safety, and tolerability comprising treatment-related death, treatment discontinuation and commonly reported grade 3 or 4 adverse events (AEs) were extracted. Associations between these measures and reporting of HRQoL data were explored using logistic regression. Of 377 phase III RCTs identified initially, 143 studies were analysed and comprised 55% positive trials and 90% industry sponsored trials. HRQoL was listed as an endpoint in 59% trials; and of these, only 65% reported HRQoL data. There were higher odds of reporting HRQoL data for positive trials (OR 2.05, P = .04) and trials published in journals with higher impact factor (OR 1.35, P = .01). Reporting of HRQoL was not associated with treatment-related death (OR 1.25, P = .40) or treatment discontinuation (OR 1.12, P = .61), but was positively associated with dyspnea and dermatological adverse events. HRQoL is reported in only two-thirds of RCTs that describe collecting such data. Reporting of HRQoL is associated with positive trial outcome and higher journal impact factor, but not associated with overall safety and tolerability of anti-cancer drugs.
Sections du résumé
BACKGROUND
Anti-cancer drugs are approved typically on the basis of efficacy and safety as evaluated in phase III randomized trials (RCTs). Health-related quality of life (HRQoL) is a direct measure of patient benefit, but is under-reported. Here we explore associations with reporting of HRQoL data in phase III RCTs in common solid tumors.
METHODS
We searched ClinicalTrials.gov to identify phase III RCTs evaluating new drugs in adults with advanced cancers that completed accrual between January 2005 and October 2016. Data on HRQoL, safety, and tolerability comprising treatment-related death, treatment discontinuation and commonly reported grade 3 or 4 adverse events (AEs) were extracted. Associations between these measures and reporting of HRQoL data were explored using logistic regression.
RESULTS
Of 377 phase III RCTs identified initially, 143 studies were analysed and comprised 55% positive trials and 90% industry sponsored trials. HRQoL was listed as an endpoint in 59% trials; and of these, only 65% reported HRQoL data. There were higher odds of reporting HRQoL data for positive trials (OR 2.05, P = .04) and trials published in journals with higher impact factor (OR 1.35, P = .01). Reporting of HRQoL was not associated with treatment-related death (OR 1.25, P = .40) or treatment discontinuation (OR 1.12, P = .61), but was positively associated with dyspnea and dermatological adverse events.
CONCLUSIONS
HRQoL is reported in only two-thirds of RCTs that describe collecting such data. Reporting of HRQoL is associated with positive trial outcome and higher journal impact factor, but not associated with overall safety and tolerability of anti-cancer drugs.
Identifiants
pubmed: 32886422
doi: 10.1002/cam4.3390
pmc: PMC7643655
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7888-7895Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Clin Oncol. 2015 Aug 10;33(23):2563-77
pubmed: 26101248
Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):119-28
pubmed: 20384559
JAMA Oncol. 2018 Nov 1;4(11):1610-1611
pubmed: 30267037
J Clin Oncol. 2012 Aug 20;30(24):3012-9
pubmed: 22802313
Eur Urol. 2014 Sep;66(3):416-27
pubmed: 24210091
Ann Oncol. 2007 Dec;18(12):1935-42
pubmed: 17698837
Lancet Oncol. 2016 Dec;17(12):e560-e567
pubmed: 27924754
Oncologist. 2018 Feb;23(2):203-213
pubmed: 29118265
Ann Oncol. 2016 Dec;27(12):2224-2229
pubmed: 27789469
Qual Life Res. 2013 Aug;22(6):1161-75
pubmed: 22987144
Contemp Clin Trials. 2009 Jul;30(4):289-92
pubmed: 19275948
BMC Palliat Care. 2016 Aug 02;15:72
pubmed: 27484209
Ther Adv Med Oncol. 2011 Mar;3(2):57-71
pubmed: 21789156
Ann Oncol. 2019 Apr 1;30(4):657-658
pubmed: 30698646
J Clin Oncol. 2012 Dec 1;30(34):4249-55
pubmed: 23071244
J Midlife Health. 2017 Apr-Jun;8(2):75-83
pubmed: 28706408
Int J Cancer. 2019 Apr 1;144(7):1746-1751
pubmed: 30374970
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Cancers (Basel). 2017 Jun 26;9(7):
pubmed: 28672850
J Clin Oncol. 2016 Aug 20;34(24):2925-34
pubmed: 27247218
JAMA. 2018 Feb 6;319(5):483-494
pubmed: 29411037
JAMA. 2004 Nov 3;292(17):2130-40
pubmed: 15523074
Curr Med Res Opin. 2016 Oct;32(10):1709-17
pubmed: 27331272
Ann Oncol. 2018 Dec 1;29(12):2288-2295
pubmed: 30304498
Cancer Med. 2020 Nov;9(21):7888-7895
pubmed: 32886422
Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71
pubmed: 2858114
Ann Oncol. 2015 Sep;26(9):1966-1973
pubmed: 26133966
Lancet Oncol. 2016 May;17(5):e209-19
pubmed: 27301048
Am Soc Clin Oncol Educ Book. 2019 Jan;39:374-387
pubmed: 31099613
Contemp Clin Trials. 2015 Jul;43:1-9
pubmed: 25896116
JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1225-36
pubmed: 25068501
Ann Oncol. 2015 Aug;26(8):1547-73
pubmed: 26026162
Crit Rev Oncol Hematol. 2020 Feb;146:102877
pubmed: 31981880
CA Cancer J Clin. 2007 Sep-Oct;57(5):278-300
pubmed: 17855485
Lancet Oncol. 2018 May;19(5):e267-e274
pubmed: 29726391
Patient Relat Outcome Meas. 2018 Nov 01;9:353-367
pubmed: 30464666
Stat Med. 2004 May 15;23(9):1351-75
pubmed: 15116347
JAMA. 2013 Feb 27;309(8):814-22
pubmed: 23443445
J Clin Oncol. 2007 Nov 10;25(32):5094-9
pubmed: 17991927
Lung Cancer. 2020 Jan;139:47-54
pubmed: 31734586
Afr Health Sci. 2011 Jun;11(2):266-70
pubmed: 21857860